Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 290 participants.
Also called NCT02126358
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 290 participants
- Sponsor
- Registry
-
NCT02126358
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02126358. Randomized; quadruple masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2016-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)
- Condition
- Type 2 Diabetes
- Condition
- Dyslipidemia
- Intervention (Drug)
- Gemigliptin and/or Rosuvastatin
- Lead sponsor
- LG Life Sciences
Record details
- Record id
cardio:ct-nct02126358- Content hash
adc16461fd2a4f020e56bcca14f3aad276230df0d053b7953c992eddfde48f4e